Research Topics
| James A BonnerSummaryAffiliation: University of Alabama at Birmingham Country: USA Publications
| Collaborators
|
Detail Information
Publications
Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiationJames A Bonner
Department of Radiation Oncology, The University of Alabama, Birmingham, AL 35249, USA
Radiother Oncol 101:183-9. 2011..This study focused on the interaction of cisplatin/radiation with the anti-human DR5 monoclonal antibody TRA-8 in SCLC cells. TRA-8 binds specifically to DR5 and has been shown to activate apoptosis...- Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinomaJames A Bonner
Department of Radiation Oncology, The University of Alabama at Birmingham, USA
Radiother Oncol 99:339-43. 2011.... - Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survivalJames A Bonner
University of Alabama, Birmingham, AL, USA
Lancet Oncol 11:21-8. 2010..Here we report the 5-year survival data, and investigate the relation between cetuximab-induced rash and survival... 
Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expressionJames A Bonner
Department of Radiation Oncology, The University of Alabama School of Medicine, Birmingham, 35294 3300, USA
Int J Radiat Oncol Biol Phys 59:2-10. 2004..To explore this question, cells (LS174T) that did not display inherent anti-EGFR treatment-induced radiosensitization were selected for studies that could potentially enhance EGFR expression...- Adenoviral vector-mediated augmentation of epidermal growth factor receptor (EGFr) enhances the radiosensitization properties of anti-EGFr treatment in prostate cancer cellsJames A Bonner
Department of Radiation Oncology, University of Alabama School of Medicine, Birmingham, Alabama, USA
Int J Radiat Oncol Biol Phys 58:950-8. 2004.... - Dosimetric factors associated with long-term dysphagia after definitive radiotherapy for squamous cell carcinoma of the head and neckJimmy J Caudell
Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35249, USA
Int J Radiat Oncol Biol Phys 76:403-9. 2010..Intensification of radiotherapy and chemotherapy for head-and-neck cancer may lead to increased rates of dysphagia. Dosimetric predictors of objective findings of long-term dysphagia were sought... - Gastrostomy tube placement and use in patients with head and neck cancerJulie L Locher
Department of Medicine, Division of Gerontology, Geriatrics, and Palliative Care, University of Alabama at Birmingham, Birmingham, Alabama, USA
Head Neck 34:422-8. 2012..This study describes the frequency and timing of gastrostomy tube placement and corresponding Medicare nutritional support claims in patients with head and neck cancer... - Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckJames A Bonner
Department of Medicine, University of Alabama, Birmingham, USA
N Engl J Med 354:567-78. 2006.... - Site-specifically traced drug release and biodistribution of a paclitaxel-antibody conjugate toward improvement of the linker structureAhmad Safavy
Department of Radiation Oncology and Medicine, Biostatistics and Bioinformatics Unit, and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
Bioconjug Chem 15:1264-74. 2004..These results demonstrated the first time use of radioiodinated 3'-OH-PTX for in vivo tracing of a paclitaxel conjugate and application of the resulting information to the design of a therapeutically more useful PTX-MAb linker... - Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53)Steven E Schild
Mayo Clinic Arizona, Department of Radiation Oncology, Scottsdale, AZ 85259, USA
J Clin Oncol 25:3124-9. 2007..To evaluate the outcome of patients with limited-stage small-cell lung cancer (L-SCLC) treated with cisplatin and etoposide (PE), early prophylactic cranial irradiation (PCI), and high-dose twice-daily thoracic radiotherapy (bid RT)... 
Synthesis and preliminary biological evaluation of high-drug-load paclitaxel-antibody conjugates for tumor-targeted chemotherapySherly Quiles
Department of Radiation Oncology, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
J Med Chem 53:586-94. 2010..These conjugates may have potential in the development of high-drug-load tumor-targeting taxanes...- Adjuvant radiotherapy for pancreatic cancer is associated with a survival benefit primarily in stage IIB patientsJohn S Moody
Department of Radiation Oncology, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294 3300, USA
J Gastroenterol 44:84-91. 2009..This study examines the survival impact of postoperative RT in a large population-based database... - Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancerAleksandar F Dragovic
Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA
Head Neck 33:1551-6. 2011..We investigated patient outcomes using a new parameter: the average weekly dose (AWD)... - Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancerJimmy J Caudell
Department of Radiation Oncology, University of Alabama Birmingham, Birmingham, AL, USA
Int J Radiat Oncol Biol Phys 73:410-5. 2009..The use of altered fractionation radiotherapy (RT) regimens, as well as concomitant chemotherapy and RT, to intensify therapy for locally advanced head-and-neck cancer can lead to increased rates of long-term dysphagia... - Dosimetric analysis of imaging changes following pulmonary stereotactic body radiation therapyBrendan M Prendergast
Department of Radiation Oncology Thoracic Surgery, University of Alabama, Birmingham, Alabama, USA
J Med Imaging Radiat Oncol 55:90-6. 2011..The aim of this study was to determine whether late patterns of pulmonary fibrosis are related to specific radiation doses administered during thoracic stereotactic body radiation therapy (SBRT)... - Kinomic profiling approach identifies Trk as a novel radiation modulatorJohn S Jarboe
Department of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL 35249 6832, USA
Radiother Oncol 103:380-7. 2012..Ionizing radiation treatment is used in over half of all cancer patients, thus determining the mechanisms of response or resistance is critical for the development of novel treatment approaches... - Small-cell lung cancer: prognostic factors and changing treatment over 15 yearsLaurie E Gaspar
University of Colorado School of Medicine, Department of Radiation Oncology, 1665 Aurora Court, Suite 1032, MS F706, Aurora, CO 80045 0510, USA
Clin Lung Cancer 13:115-22. 2012..Sixty-eight thousand six hundred eleven patients with SCLC in the National Cancer Data Base (NCDB) were analyzed to describe demographic, treatment, and survival changes between 1992 and 2007... - HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repairSomaira Nowsheen
Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, USA
Cancer Res 72:4796-806. 2012..Our findings indicate that PARP inhibitors may be a novel therapeutic strategy for sporadic HER2+ breast cancer patients... - Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinomaJames A Bonner
Department of Radiation Oncology, The University of Alabama at Birmingham, AL 35233, USA
Radiother Oncol 92:339-44. 2009..Studies were performed to determine if inhibition of this downstream protein produces radiosensitization... - Comparison of methods to reduce dose to swallowing-related structures in head and neck cancerJimmy J Caudell
Department of Radiation Oncology, University of Alabama at Birmingham, USA
Int J Radiat Oncol Biol Phys 77:462-7. 2010..Organ avoidance becomes difficult when the primary tumor or involved nodes are present at the level of the larynx... - Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibodyZhi-qiang Huang
Division of General Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama 35294-0016, USA
J Surg Res 111:274-83. 2003.... - The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapySomaira Nowsheen
Department of Radiation Oncology, University of Alabama at Birmingham School of Medicine, USA
Radiother Oncol 99:331-8. 2011..Thus, we studied whether inhibition of poly(ADP-Ribose) polymerase (PARP), a key DNA repair enzyme, could improve efficacy of radiotherapy in human head and neck cancer... - Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiationDonald J Buchsbaum
Department of Radiation Oncology, University of Alabama at Birmingham, Wallace Tumor Institute, Room 674, 1824 6th Avenue South, Birmingham, AL 35294, USA
Int J Radiat Oncol Biol Phys 54:1180-93. 2002..To investigate treatment of human pancreatic cancer cell lines and xenografts with combinations of Erbitux (IMC-C225) anti-epidermal growth factor receptor (EGFR) antibody, gemcitabine, and radiation... - Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer modelsZhuo Zhang
Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama 35294-0019, USA
Clin Cancer Res 10:1263-73. 2004.... - Examination of laryngoesophageal dysfunction-free survival as an endpoint in nonsurgical treatment of squamous cell carcinomas of the larynx and hypopharynxJimmy J Caudell
Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, Mississippi, USA
Cancer 117:4447-51. 2011..The authors of this report examined LEDFS in the context of definitive radiotherapy alone (RT) or with concurrent chemoradiotherapy (CRT)... - Margin on gross tumor volume and risk of local recurrence in head-and-neck cancerJimmy J Caudell
Department of Radiation Oncology, University of Alabama Birmingham, Birmingham, AL 35249, USA
Int J Radiat Oncol Biol Phys 76:164-8. 2010.... - Validation of target volume and position in respiratory gated CT planning and treatmentSui Shen
Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama 35233, USA
Med Phys 30:3196-205. 2003..5-2.5 mm safety margin can be added regardless of the size of residual motion error. For respiratory rates > or = 30 cycles/min, the effectiveness of gating is limited by large residual motion in the 1 s CT acquisition time... - Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug deliveryAhmad Safavy
Department of Radiation Oncology, Biostatistics Unit, University of Alabama at Birmingham, 35294, USA
Bioconjug Chem 14:302-10. 2003.... - Design and development of water-soluble curcumin conjugates as potential anticancer agentsAhmad Safavy
Department of Radiation Oncology, University of Alabama at Birmingham, 1824 6th Avenue S, Birmingham, AL 35294 6832, USA
J Med Chem 50:6284-8. 2007..Synthesis, analyses of the rate of drug release, and cytotoxicity studies are herein reported. The water-soluble conjugates may provide information useful for the development of injectable curcumin conjugates... - Dosimetric impact of target definitions on normal structures in head and neck cancerMicah T Monaghan
Department of Radiation Oncology, The University of Alabama at Birmingham, 1700 Sixth Avenue South, Birmingham, AL 35249, USA
Head Neck Oncol 3:34. 2011..Previous work by our group suggests smaller target volumes may result in equivalent locoregional control for head and neck cancer. We evaluated whether smaller target volumes may also result in improved normal tissue sparing... - Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214Elizabeth M Gore
Department of Radiation Oncology, Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53213, USA
J Clin Oncol 29:272-8. 2011..This study was conducted to determine if prophylactic cranial irradiation (PCI) improves survival in locally advanced non-small-cell lung cancer (LA-NSCLC)... - Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancerSomaira Nowsheen
Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States of America
PLoS ONE 6:e24148. 2011..Furthermore, this strategy may also be feasible for other EGFR overexpressing tumors, including lung and brain cancers... - RapidArc radiation therapy: first year experience at the University of Alabama at BirminghamRichard A Popple
Department of Radiation Oncology, The University of Alabama at Birmingham, Birmingham, Alabama, USA
Int J Radiat Oncol Biol Phys 77:932-41. 2010..To evaluate treatment planning and delivery for patients treated during our initial year of experience with RapidArc radiation therapy... - MARCKS regulates growth and radiation sensitivity and is a novel prognostic factor for gliomaJohn S Jarboe
The Departments of Radiation Oncology, The University of Alabama at Birmingham, Birmingham, AL 35249, USA
Clin Cancer Res 18:3030-41. 2012..This study assessed whether myristoylated alanine-rich C-kinase substrate (MARCKS) can regulate glioblastoma multiforme (GBM) growth, radiation sensitivity, and clinical outcome... - Prophylactic percutaneous endoscopic gastrostomy tube placement in treatment of head and neck cancer: a comprehensive review and call for evidence-based medicineJulie L Locher
Department of Medicine, Division of Gerontology, University of Alabama at Birmingham, Birmingham, Alabama, USA
JPEN J Parenter Enteral Nutr 35:365-74. 2011..PEG tube placement, however, is not without risks... - Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatmentJimmy J Caudell
Department of Radiation Oncology, University of Alabama Birmingham, Birmingham, AL 35249, USA
Int J Radiat Oncol Biol Phys 71:676-81. 2008..However the optimal treatment regimen has not been defined. A retrospective study was performed to compare outcomes in patients who were treated definitively with ExRT or ChRT... - Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategiesMarcus M Wagner
Department of Radiation Oncology, University of Alabama at Birmingham, Hazelrig Salter Radiation Oncology Center, 1700 6th Avenue South, Birmingham, AL 35249 6832, USA
Radiat Oncol 7:219. 2012..A retrospective review of our experience was performed... - Locoregional failure and the risk of distant metastasis after modern radiotherapy for head and neck cancerAleksandar F Dragovic
Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama 35233, USA
Head Neck 35:381-7. 2013..Evolving epidemiology and improvements in locoregional therapy necessitate reassessment of the relationship between locoregional failure and distant metastasis in squamous cell carcinoma of the head and neck (SCCHN)... - Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderlySteven E Schild
Department of Radiation Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
Cancer 103:2349-54. 2005..No difference in survival was identified between the two arms. The current analysis examined the relation between age and outcome for patients treated during this trial... - Stage-specific survival differences associated with postoperative radiotherapy for gastrointestinal cancersJohn S Moody
Department of Radiation Oncology, University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
J Gastrointest Cancer 39:86-99. 2008..To study the frequency and effect associated with postoperative radiotherapy (RT) for patients with resected gastrointestinal (GI) cancers... - Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data BaseLaurie E Gaspar
Department of Radiation Oncology, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045 0510, USA
Clin Lung Cancer 6:355-60. 2005..These results demonstrate the continued need for the evaluation of new treatments in this group of patients... - Diagnosis-to-treatment interval and control of locoregionally advanced head and neck cancerJimmy J Caudell
Department of Radiation Oncology, University of Mississippi Medical Center, 350 Woodrow Wilson Dr, Ste 1600, Jackson, MS 39213, USA
Arch Otolaryngol Head Neck Surg 137:282-5. 2011..To assess the impact of prolonged diagnosis-to-treatment interval (DTI) that falls in the time frame associated with the increasing complexity of planning treatment for patients with locoregionally advanced head and neck cancer (LAHNC)... - Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumorsCaroline N Mills
Department of Radiation Oncology, Comprehensive Cancer Center, University of Alabama Birmingham School of Medicine Birmingham, AL, USA
Front Mol Neurosci 4:47. 2011..A thorough understanding of this versatile protein is critical for improving the outcome of various diseases, especially cancer... - Model prediction of treatment planning for dose-fractionated radioimmunotherapySui Shen
Department of Radiation Oncology, University of Alabama at Birmingham, 35294, USA
Cancer 94:1264-9. 2002..Clinical trials of radioimmunotherapy (RIT) often use dose fractionation to reduce marrow toxicity. The dosing scheme can be optimized if marrow and tumor cell kinetics following radiation exposure are known... - Biology of interactions: antiepidermal growth factor receptor agentsPaul M Harari
Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
J Clin Oncol 25:4057-65. 2007..Many questions remain to be answered, particularly with regard to how best combine EGFR inhibitors with conventional cancer therapies, and how to select those patients (tumors) most likely to benefit from EGFR inhibition strategies... - More on severe cutaneous reaction with radiotherapy and cetuximabJames A Bonner
N Engl J Med 357:1872-3; author reply 1873. 2007 - Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximabDesmond Curran
Omega Research, Dublin, Ireland
J Clin Oncol 25:2191-7. 2007..In this randomized, phase III study, quality of life (QoL) was assessed in patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) after high-dose radiotherapy alone or in combination with cetuximab... - Patterns of surgical care of lung cancer patientsAlex G Little
Department of Surgery, Wright State University School of Medicine, Dayton, Ohio, USA
Ann Thorac Surg 80:2051-6; discussion 2056. 2005..This survey was performed to determine the patterns of surgical care provided patients with non-small cell lung carcinoma (NSCLC)... - Epidermal growth factor receptor as a therapeutic target in head and neck cancerJames A Bonner
University of Alabama at Birmingham, 35294-3300, USA
Semin Radiat Oncol 12:11-20. 2002.... - Smoking behavior of 226 patients with diagnosis of stage IIIA/IIIB non-small cell lung cancerLisa Sanderson Cox
Nicotine Research Program, Mayo Clinic, Rochester, MN 55905, USA
Psychooncology 11:472-8. 2002..Smoking cessation interventions are needed for lung cancer patients who continue to smoke... - A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734Michael C Perry
University of Missouri Ellis Fischel Cancer Center, Columbia, MO 65203, USA
Clin Lung Cancer 8:268-72. 2007..We added adjuvant chemotherapy to control presumed micrometastatic disease and then randomized patients to receive radiation therapy (RT) or observation to determine the benefit of local radiation consolidation... - Postoperative radiotherapy in non-small-cell lung cancer warrants further exploration in the era of adjuvant chemotherapy and conformal radiotherapyJames A Bonner
J Clin Oncol 24:2978-80. 2006 - Intraoperative radiotherapy for head and neck and skull base cancerA Daniel Pinheiro
Department of Otorhinolaryngology, Mayo Clinic, Rochester, Minnesota 55905, USA
Head Neck 25:217-25; discussion 225-6. 2003..5 Gy (cumulative dose 130.1 Gy). CONCLUSIONS: IORT at a dose of 12.5 Gy is safe and produces tumor control and survival for patients likely to have microscopic residual disease in sites difficult to resect such as the skull base... - A quality-adjusted reanalysis of a Phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer(1)Jeff A Sloan
Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Int J Radiat Oncol Biol Phys 52:371-81. 2002.... - The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderlySteven E Schild
Mayo Clinic and Mayo Foundation, Rochester, MN, USA
J Clin Oncol 21:3201-6. 2003..No difference in survival was identified between the two arms. This secondary analysis was performed to examine the relationship between patient age and outcome... - Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I studyMichael C Dobelbower
University of Alabama at Birmingham, Alabama 35249-6832, USA
Anticancer Drugs 17:95-102. 2006..The major toxicities encountered were grade 1-2 diarrhea, grade 1 skin rash, grade 1-3 nausea and grade 3 dehydration. A phase II study is planned... - Quality of life in 650 lung cancer survivors 6 months to 4 years after diagnosisAdam Svobodnik
Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Mayo Clin Proc 79:1024-30. 2004..To present the results of a quality-of-life (QOL) assessment performed with the current version of the Lung Cancer Symptom Scale (LCSS) questionnaire in a large single-institutional data set of 650 patients with lung cancer... - Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancerSteven E Schild
Mayo Clinic and Mayo Foundation, Rochester, MN, USA
Int J Radiat Oncol Biol Phys 59:943-51. 2004..This Phase III study was performed to determine whether twice-daily (b.i.d.) radiotherapy (RT) resulted in better survival than once-daily (q.d.) RT for patients with limited-stage small-cell lung cancer (LD-SCLC)...